ABCL Stock Catalyst: AbCellera to Announce Top-Line Results from Phase 2 Trial of ABCL635 for Menopause Symptoms

Aug 7, 2026 · 4:29pm ET

Company to disclose outcomes for moderate-to-severe vasomotor symptoms treatment.

Max move

+44.4%

High of day $10.01

Sparker timei

4:29pm ET

ABCL · Aug 7, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

AbCellera Biologics Inc. (Nasdaq: ABCL) announced it will reveal top-line results from the Phase 2 trial of its drug candidate ABCL635, aimed at treating moderate-to-severe vasomotor symptoms (VMS) due to menopause, on Monday, August 10, 2026.

The trial evaluated the efficacy and safety of ABCL635 in reducing VMS frequency and severity in menopausal women. AbCellera did not provide specific data points or comparisons in the announcement.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ABCL sparks.

Download Sniper App →

Catch the next ABCL-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →